Get regular updates to your inbox.
Dosing is underway in a Phase 2 clinical trial of MBX 2109, an investigational hormone replacement therapy for people with hypoparathyroidism, according to the therapy’s developer, MBX Biosciences, with top-line expected around mid-2025. The trial, called Avail (NCT06465108), is evaluating the safety, effectiveness, and pharmacological properties…
Permanent hypoparathyroidism, which can occur when the parathyroid glands are accidentally removed along with the thyroid gland during a surgical procedure, increases the risk of kidney damage over time, according to a study by researchers in Hong Kong. “Careful patient selection and improvement in the identification and preservation of…
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma’s Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism. The company expects to have the first supply ready in early 2025 after it completes manufacturing for the U.S. market. But if the FDA clears…
Long-lasting hypoparathyroidism following surgery is associated with more hospitalizations and higher healthcare-related medical costs compared with temporary hypoparathyroidism after surgery, a new U.S. study shows. The higher medical costs linked to such chronic disease were found to create a greater economic burden for patients, according to researchers. For one…
Even with conventional treatment, health complications including the formation of calcium deposits in the brain, cataracts in the eyes, and kidney stones are frequent among people with chronic hypoparathyroidism, especially those who’ve been living with the condition for a long time, according to an analysis of patients at a…
Treatment with Ascendis Pharma’s TransCon PTH (palopegteriparatide) for up to two years leads to sustained improvements in the kidney function of adults with chronic hypoparathyroidism. That’s according to an analysis of data from PaTHway (NCT04701203), a Phase 3 clinical trial of TransCon PTH. A decision from the…
The U.S. Food and Drug Administration (FDA) is delaying by three months its decision to approve Ascendis Pharma’s TransCon PTH (palopegteriparatide) as a hormone replacement therapy for adults with hypoparathyroidism. The FDA decided not to approve the investigational therapy in April 2023 over concerns about its manufacturing…
The U.S. Food and Drug Administration (FDA) has given fast track designation to eneboparatide, an experimental treatment for hypoparathyroidism that’s being investigated in a global Phase 3 clinical trial. This designation is intended to speed the development of therapies with the potential to address major unmet needs for serious…
Slightly less than 20% of people who had their thyroid gland removed had hypoparathyroidism a year after the surgery, according to a 20-year study in Denmark. An increase in mortality risk was only found when the the surgery was due to cancer, but mortality was unaffected in benign cases.
About one in five adults with hypoparathyroidism had impaired kidney function, according to a study based on real-life data. Ultrasounds also revealed calcium deposits in the kidneys of 10% of patients, which were predicted by low phosphate in the bloodstream and longer disease duration. The deposits didn’t appear to…
Get regular updates to your inbox.